City of Hope's Robert Morgan, M.D., on bevacizumab study for advanced cervical cancer @ ASCO



Avastin Boosts Survival in Cervical Cancer

Survival improved in patients with difficult to treat cases of cervical cancer.

By John Gever, MedPage Today

Don't Miss This

Sign Up for OurCancer Care and PreventionNewsletter

Thanks for signing up!You might also like these other newsletters:

THURSDAY, Feb. 7, 2013 (MedPage Today) —Overall survival among patients with cervical cancer not curable with standard treatment was improved significantly when bevacizumab (Avastin) was added to either of two chemotherapy regimens, the National Cancer Institute (NCI) announced.

Median overall survival in patients treated with bevacizumab and chemotherapy in a randomized trial was 17 months, compared with 13.3 months in patients treated with chemotherapy alone, according to top-line results of an interim analysis released late Thursday in an NCI press release.

The release did not give aPvalue for the difference, but the NCI called it "highly statistically significant."

"The data safety monitoring committee overseeing the trial recommended that the results of a recent interim analysis be made public because the study had met its primary endpoint of demonstrating improved overall survival in patients who received bevacizumab," the NCI said.

More adverse effects were seen in patients receiving bevacizumab, the agency noted. The pattern was similar to that seen with bevacizumab in other settings.

No other specific results were given in the release. It said full data would be submitted for presentation at the American Society of Clinical Oncology's annual meeting, which begins May 31.

The NCI-funded trial is called GOG240 and involves 452 patients in the U.S. and Spain with recurrent, persistent, or metastatic cervical cancer that cannot be cured with standard treatments, the agency said.

Patients in the trial were assigned to four treatment arms: cisplatin plus paclitaxel (the current standard of care), topotecan plus paclitaxel, or the same two regimens with bevacizumab added. The latter drug was given at 15 mg/kg every 3 weeks until disease progression or excessive toxicity was seen.

An earlier interim analysis had found that the two chemotherapy regimens alone were equivalent, the NCI said.






Video: Safety Findings of Long-Term Bevacizumab for Patients with Ovarian Cancer

Avastin Boosts Survival in Cervical Cancer
Avastin Boosts Survival in Cervical Cancer images

2019 year
2019 year - Avastin Boosts Survival in Cervical Cancer pictures

Avastin Boosts Survival in Cervical Cancer recommend
Avastin Boosts Survival in Cervical Cancer forecast photo

Avastin Boosts Survival in Cervical Cancer picture
Avastin Boosts Survival in Cervical Cancer picture

Avastin Boosts Survival in Cervical Cancer Avastin Boosts Survival in Cervical Cancer new pics
Avastin Boosts Survival in Cervical Cancer new foto

photo Avastin Boosts Survival in Cervical Cancer
images Avastin Boosts Survival in Cervical Cancer

Watch Avastin Boosts Survival in Cervical Cancer video
Watch Avastin Boosts Survival in Cervical Cancer video

Discussion on this topic: Avastin Boosts Survival in Cervical Cancer, avastin-boosts-survival-in-cervical-cancer/
Communication on this topic: Avastin Boosts Survival in Cervical Cancer, avastin-boosts-survival-in-cervical-cancer/ , avastin-boosts-survival-in-cervical-cancer/

Related News


7-Minute Butt Lifting Workout
8 Signs Stress Is Making You Sick—And How To Get Healthier, Starting Today
US midterms: What they mean for the 2020 presidential race
Cycloserine
5 Simple Styling Lessons From Kate Bosworth To Try Now
Why Fifty Shades of Grey is good for women (and their sex lives)
How to Obtain Good Customer Service and Ensure You Are Being Helped Properly
Fitness blogger teaches us to ScrewTheScales
How to Treat Chinch Bugs Without Chemicals
Tacrolimus Reviews
5 Ways To Deal With Ageism In The Workplace
Your Year Ahead Horoscopes: Scorpio
How to Cook Pasta Al Dente
5 Ways to Cut Sugar



Date: 01.12.2018, 08:26 / Views: 41332